Abu Dhabi Public Health Centre Partners With Novartis To Enhance Disease Prevention And Awareness

The Abu Dhabi Public Health Centre (ADPHC) has partnered with Novartis Middle East FZE to enhance health awareness and disease management in the Abu Dhabi Emirate. This collaboration focuses on cardiovascular diseases, diabetes, and chronic kidney disease. The agreement was formalised on May 13 during the 25th IUHPE World Conference on Health Promotion at the Abu Dhabi National Exhibition Centre.

Dr. Rashed Obaid Alsuwaidi of ADPHC expressed that this partnership is crucial for strengthening public health systems and reducing non-communicable diseases' impact. He emphasised the goal of achieving sustainable health outcomes through strategic alliances. Mohamed Ezz Eldin from Novartis highlighted their shared mission to improve patient care by reimagining medicine and promoting early detection and proactive disease management.

This two-year agreement between ADPHC and Novartis aims to promote healthier lifestyles in Abu Dhabi through innovative public health strategies. The collaboration will focus on raising awareness about risk factors, early symptoms, and the importance of regular screenings for non-communicable diseases using both digital and traditional channels.

The partnership is structured around three main pillars: disease awareness, prevention, and best practice sharing in disease management. These initiatives aim to educate communities about conditions like cardiovascular diseases, diabetes, and chronic kidney disease while encouraging proactive health behaviours such as routine testing.

Efforts will include designing initiatives for primary prevention of adult cardiovascular diseases, diabetes, and chronic kidney disease. Targeted screening activities will help identify individuals at risk early. By focusing on these areas, the collaboration seeks to improve patient outcomes and healthcare system performance.

A dedicated task force will be established under the MoU to coordinate efforts between ADPHC and Novartis. Each party will appoint a lead to oversee project plans, assess feasibility, define key deliverables, and evaluate outcomes based on jointly agreed key performance indicators (KPIs).

Commitment to Best Practices

The task force will meet regularly to ensure alignment with strategic goals and adapt to emerging public health needs. Best practices across the patient journey will be identified, shared, and implemented. This includes early screening protocols, preventive strategies, and disease management models drawing from global expertise.

The KPIs will be reviewed biannually to ensure they align with strategic objectives. This approach ensures that both parties can respond effectively to changing public health demands while maintaining a focus on improving community well-being in Abu Dhabi.

This collaboration underscores a mutual commitment between ADPHC and Novartis to leverage public health approaches alongside private sector innovation. By working together, they aim to make a measurable impact on people's lives through increased awareness, early detection, and proactive disease management strategies.

With inputs from WAM